Morepen Laboratories Ltd.

₹38.11

-2.1 (-5.3%)

MOREPENLAB Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,088 Cr

P/E Ratio17.69

Dividend Yield0.26 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	39.64	Bearish
10-DMA	40.48	Bearish
20-DMA	40.83	Bearish
50-DMA	39.12	Bearish
100-DMA	41.71	Bearish
200-DMA	48.92	Bearish

Historical Performance

1 Year

-14.6%

3 Years

51.2%

5 Years

6.9%

10 Years

40.9%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	18,116	16,904	14,175	15,468	11,881
Total Expenditure	16,375	15,318	13,380	14,102	10,695
Other Income	184	140	61	201	121
Operating Profit	1,924	1,726	857	1,568	1,306
Interest	83	37	20	24	18
Depreciation	290	335	279	276	303
Profit Before Tax	1,551	1,354	558	1,267	985
Consolidated Net Profit	1,180	962	387	1,017	971
Adjusted EPS	2	2	1	2	2

Compounded Sales Growth

10 Years:35.2

5 Years:16.3

3 Years:3.2

TTM:1.4

Compounded Profit Growth

10 Years:123

5 Years:28.6

3 Years:3

TTM:4.2

Stock Price CAGR

10 Years:3.9

5 Years:1.6

3 Years:15.4

TTM:-14.6

Return on Equity

10 Years:0.3

5 Years:2.2

3 Years:0.8

last year:2.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	1,096	1,022	1,022	956	900
Total Reserves	10,466	7,450	6,507	4,568	2,910
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	905	439	369	355	301
Other Current Liabilities	717	585	549	1,700	1,744
Short Term Borrowings	460	235	232	161	153
Total Liabilities	17,781	12,932	11,105	10,700	8,581
Capital Work in Progress	283	245	170	141	20
Long Term Loans & Advances	945	708	701	695	1,035
Currents Investments	778	---	---	---	---
Short Term Loans and Advances	3,360	2,470	2,006	1,565	916
Total Current Assets	11,594	8,890	7,562	7,343	5,268
Total Assets	17,781	12,932	11,105	10,700	8,581
Adjusted Book Value	21	17	15	12	8

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 17.69, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 15.4%, indicating sustained price appreciation.
The stock carries a high beta of 1.7, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹1924 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹18116 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 889589.2

No. of Shares: 23343 (Approx)

Performance:-11%

P/L: ₹-110410.8

NIFTY Performance: 3.4%

1 day Top Gainers